Jarden Corporation (NYSE: JAH) Closed at $12.74. Today announced an update on its strong liquidity position, as well as estimated fourth quarter and full year 2008 revenue. The Company expects that revenue for the fourth quarter of 2008 will be slightly above the provided guidance of $1.3 billion. Full year revenue for 2008 is expected to be approximately $5.35 billion. In addition, based on initial submissions, the Company finished the year with more than $360 million of cash on the balance sheet. Accordingly, the Company anticipates that its leverage ratio for bank purposes at December 31, 2008 will be approximately 3.7 times.
What They Do: Jarden Corporation is a leading provider of niche consumer products. Jarden operates in three primary business segments through a number of well recognized brands.
How They Trade: JAH has a 52 week high of $27.93 and a 52 week low of $7.20.
Iconix Brand Group (Nasdaq: ICON) Closed at $9.78. Today announced that Target Corporation (NYSE: TGT) has renewed its direct-to-retail license agreement for Iconix's Mossimo brand through January 31, 2012. Mossimo has been licensed exclusively to Target in the U.S. since 2000.
What They Do: Iconix Brand Group, Inc. (Nasdaq: ICON) owns, licenses and markets a growing portfolio of consumer brands including CANDIE'S®, BONGO®, BADGLEY MISCHKA®, JOE BOXER®, RAMPAGE®, MUDD®, LONDON FOG®, MOSSIMO®, OCEAN PACIFIC®, DANSKIN®, ROCA WEAR®, CANNON®, ROYAL VELVET®, FIELDCREST®, CHARISMA®, STARTER® and WAVERLY®.
How They Trade: ICON has a 52 week high of $22.80 and a 52 week low of $5.11.
Synta Pharmaceuticals Corp. (Nasdaq: SNTA) Closed at $6.45 andRoche (SWX: ROG), Today announced the formation of a strategic alliance to discover, develop, and commercialize small-molecule drugs targeting a novel family of ion channels that are critical to immune cell function, known as calcium release-activated calcium modulator (CRACM) channels. In preclinical models, the CRACM inhibitors discovered by Synta potently and selectively inhibit the secretion of pro-inflammatory factors such as TNF-alpha and IL-2, with minimal effects on other cells or signaling pathways. This program represents a new category of oral, targeted, disease-modifying agents for treating rheumatoid arthritis and a broad range of other inflammatory diseases.
What They Do: Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.
How They Trade: SNTA has a 52 week high of $10.30 and a 52 week low of $4.29.
Clean Diesel Technologies (Nasdaq: CDTI) Closed at $2.78. Today announced along with Eaton Corporation (NYSE: ETV) that they have entered into a global non-exclusive licensing agreement. Under the agreement, Eaton will use Clean Diesel's patented Advanced Reagent Injector System (ARIS(r)) technology for injection of hydrocarbon fuel in emissions reduction applications, including Eaton's Aftertreatment System. This technology can also be applied to regeneration of diesel particulate filters and lean NOx traps in various global applications.
What They Do: Clean Diesel Technologies is a cleantech company providing sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road engine applications.
How They Trade: CDTI has a 52 week high of $23.55 and a 52 week low of $1.54.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/subscribe.htm
